Everything below concerns lipodystrophy. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
The German Islands of Sylt, Föhr, Pellworm, Amrum, Heligoland and Fehmarn are part of Schleswig-Holstein, with the latter being the largest and the only Island of Schleswig-Holstein located on the east coast. Heligoland is Germany's only high-sea island.
On February 15, 2002, the A&W Revenue Royalties Income Fund was listed on the Toronto Stock Exchange. The initial public offering was 8.34 million units at $10 each. The fund owns the A&W trademarks in Canada and licenses them to A&W Food Services of Canada Inc. Revenue is generated by charging a three percent royalty on gross sales of each restaurant. Television advertisements are filmed at locations in the Fraser Valley. In June 2006, A&W celebrated 50 years in Canada. Some Quebec A&W locations were co-branded with Dunkin' Donuts until Dunkin' Donuts closed most locations in Quebec. Two new restaurant concepts were introduced in the fall of 2009. The new standalone restaurant design is ultra modern but with some architectural markings reminiscent of the design in the earlier buildings erect from A&W back in time. There is also a new separate format for urban (i.e., downtown) locations, where some of the baby-boomer aspects are scaled back in favour of a more modern look. On November 21, 2013, the chain opened its 800th location in downtown Montreal. The company's advertising also shifted to a focus on animal welfare, such as chicken and beef raised without antibiotics. In February 2018, Susan Senecal became the company's chief executive officer. In June 2018, A&W announced that they were replacing plastic straws in their locations with paper ones, becoming the first fast food chain in North America to make the switch.
=== Insertion === For insertion in mice, a permanent ICV guide cannula must be inserted 1 mm above the lateral ventricle. A trained surgeon is ideal for insertion, and a stereotaxic frame and bone cement are needed. The cannula is implanted through the hindlimb area of the cerebral cortex. The surgeon must be careful to minimize damage to the surrounding brain tissue during this process. A catheter connected to a subcutaneous reservoir is implanted for permanent access in humans. The reservoir used is most commonly the Ommaya reservoir. A 25-gauge needle is used to puncture the scalp into the reservoir. A few milliliters of CSF are withdrawn before injecting the drug. This technique is typically used for long-term drug administration. Rarely will repeated taps be conducted to administer drugs due to the risk of damaging brain tissue.
Sources: en.wikipedia.org
=== Classic genetic mutations === Drosophila genes are traditionally named after the phenotype they cause when mutated. For example, the absence of a particular gene in Drosophila will result in a mutant embryo that does not develop a heart. Scientists have thus called this gene tinman, named after the Oz character of the same name. Likewise changes in the Shavenbaby gene cause the loss of dorsal cuticular hairs in Drosophila sechellia larvae. This system of nomenclature results in a wider range of gene names than in other organisms.
=== Visualization === The three most popular ways of visualizing the alpha-helical secondary structure of oligopeptide sequences are (1) a helical wheel, (2) a wenxiang diagram, and (3) a helical net. Each of these can be visualized with various software packages and web servers. To generate a small number of diagrams, Heliquest can be used for helical wheels, and NetWheels can be used for helical wheels and helical nets. To programmatically generate a large number of diagrams, helixvis can be used to draw helical wheels and wenxiang diagrams in the R and Python programming languages.
== Clinical trials == ACD856 has completed phase 1 clinical trials for Alzheimer's disease. As of May 2024, it was in the preclinical stage of development for depressive disorders, sleep disorders, and traumatic brain injuries. Two phase 1 trials had been completed by 2022. A further phase 1b trial, assessing the safety and tolerability of repeated higher doses, reached its last patient visit in April 2026, and results were reported in June 2026. A phase 2 clinical trial in Alzheimer's disease was expected to start in 2026, supported by a €2.5 million European Innovation Council Accelerator grant awarded in 2025. The drug was developed by AlzeCure Pharma AB, which in July 2026 out-licensed worldwide rights to ACD856 and the NeuroRestore platform to the Danish company QuantumCell ApS for US$12 million upfront, with development and commercial milestone payments that could exceed US$2.2 billion.
Sources: en.wikipedia.org
== See also == Lysergamide § Related compounds Substituted isotryptamine List of investigational hallucinogens and entactogens List of miscellaneous 5-HT2A receptor agonists Non-hallucinogenic 5-HT2A receptor agonist BOL-148 (2-bromo-LSD) and SPT-348 SDZ SER-082 DLX-0002700 LEK-8829 LSD-Quinoline
=== Other anabolic agents === Clenbuterol – a beta-agonist; anabolic ability dubious Selective androgen receptor modulators (SARMs) Tibolone – a synthetic steroid Zeranol – a nonsteroidal estrogen Zilpaterol – a beta2-agnoist; anabolic ability dubious
Anguilla - The Scout Association of Anguilla Bermuda - Bermuda Scout Association Cayman Islands - The Scout Association of the Cayman Islands Falkland Islands - Scouting and Guiding in the Falkland Islands Gibraltar - The Scout Association of Gibraltar Montserrat - The Scout Association of Montserrat Saint Helena and Ascension Island - Scouting and Guiding on Saint Helena and Ascension Island Turks and Caicos Islands - The Scout Association of the Turks and Caicos British Virgin Islands - The Scout Association of the British Virgin Islands United States
The ruddy bowfin (Amia calva) is a ray-finned fish native to North America. Common names include mudfish, mud pike, dogfish, grindle, grinnel, swamp trout, and choupique. It is regarded as a relict, being one of only two surviving species of the Halecomorphi, a group of fish that first appeared during the Early Triassic, around 250 million years ago. The bowfin is often considered a "living fossil" because it has retained some morphological characteristics of its early ancestors. It is one of two species in the genus Amia, along with Amia ocellicauda, the eyespot bowfin. The closest living relatives of bowfins are gars, with the two groups being united in the clade Holostei. Bowfins are demersal, freshwater piscivores, commonly found throughout much of the Eastern United States, and southern Ontario and Quebec. Fossil deposits indicate the Amiiformes were once widespread in both freshwater and marine environments across North and South America, Europe, Asia, and Africa. Now, their range is limited to much of the Eastern United States and adjacent southern Canada, including the drainage basins of the Mississippi River, Great Lakes, and various rivers exiting in the Eastern Seaboard or Gulf of Mexico. Their preferred habitat includes vegetated sloughs, lowland rivers and lakes, swamps, and backwater areas; they are also occasionally found in brackish water. They are stalking, ambush predators known to move into the shallows at night to prey on fish and aquatic invertebrates such as crawfish, mollusks, and aquatic insects.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.